Navigation Links
Watson Announces Preliminary 2011 Non-GAAP Earnings of $4.75-$4.77
Date:1/24/2012

PARSIPPANY, N.J., Jan. 24, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced preliminary 2011 non-GAAP earnings per share of $4.75-$4.77, a 39 percent increase over 2010 full year earnings during its third annual Investor Meeting in New York City.  Excluding the November 2011 launch of generic Lipitor® which is expected to represent a $0.64 earnings contribution, earnings grew at approximately 20 percent for the full year.  The Company also reported preliminary full year 2011 revenues of approximately $4.57 billion, an increase of 28 percent over 2010.

"The strength of our integrated pharmaceutical business drove exceptional results last year, based on significant performance in our Global Generics business, and sound results for our Global Brands and Anda Distribution operations," said Paul Bisaro, President and CEO of Watson.  "Total revenue grew at approximately 28%, supporting the exceptional 39% growth in earnings. We ended the year with a strong balance sheet that is enabling us to support both the organic growth of our business, while being in the good position to execute on strategic business development activities and investments into all three of our businesses."

The Company noted that its Global Generics revenues of approximately $3.36 billion were driven by the launch of generic Concerta®, by higher generic Lipitor® sales resulting from its ability to maximize the launch opportunity, as well the continued strong performance of its modified-release and oral contraceptive franchises.  In addition, Watson's international generics business performed well, supported by the May 2011 strategic acquisition of Specifar.  The Company said that Global Brands revenues of approximately $440 million, and Anda Distribution revenues of approximately $776 million were in line with its full year forecasts.'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Watson Acquires Ascent Pharmahealth for AU$375 Million
2. Watson to Present at the 30th Annual J.P. Morgan Healthcare Conference
3. Watson to Present at Goldman Sachs Healthcare CEOs Unscripted: A View from the Top
4. Watson Launches Generic LoSEASONIQUE(R)
5. Watson Launches Generic LIPITOR®
6. Watson to Present at the 2011 Piper Jaffray Health Care Conference
7. Watson Wins Kentucky Drug Pricing Litigation
8. Watson Confirms Exelon(R) Patent Challenge
9. Columbia Laboratories and Watson Pharmaceuticals Confirm FDA Advisory Committee to Review Preterm Birth NDA
10. Watson Third Quarter 2011 Net Revenue Climbs 23% to $1.1 Billion; Non-GAAP Diluted EPS of $1.09; GAAP Diluted EPS of $0.54
11. Watson Confirms Court Grants Preliminary Injunction Preventing Launch of Generic LOVENOX®
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015  Immune Therapeutics, Inc. today announced ... for the compounding, packaging and distributing of its naltrexone tablets. ... the United States . KRS Global ... naltrexone tablets in various strengths for individual patients in response ...
(Date:1/23/2015)... Jan. 23, 2015  HyGreen, Inc., a leader in hand ... with RCA Medical, a subsidiary of Ascendis Health Limited, ... Each year, hundreds of millions of patients around ... organisms are transmitted from patient to patient via the ...
(Date:1/23/2015)... 23, 2015  Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT), announced that ... of Lixte,s lead compound, LB‑100, is being conducted, has been ... S. Kovach , M.D., the founder and President of Lixte, ... at a single site. Accrual of patients, however, was slower ...
Breaking Medicine Technology:Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 4HyGreen Partners with RCA Medical in Johannesburg, South Africa 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3
... Bacterin International Holdings, Inc. (NYSE Amex: ... bone graft material and antimicrobial coatings for medical applications, ... Concepts (AMC), the largest multi-specialty Orthopedic, Spine and Neuro ... The award gives Bacterin ,pre-approved, ready-access to ...
... PLANTATION, Fla. and PORTOLA VALLEY, Calif., Oct. 24, 2011 ... announced a collaboration for the process development and cGMP ... used in Phase I and Phase II clinical trials. ... is prostatectomy, or removal of the prostate," noted David ...
Cached Medicine Technology:Bacterin Awarded Approved Vendor Status for American Medical Concepts' Network of Hospitals in the Northwest U.S. 2Goodwin Biotechnology Announces a Collaboration with Spectros Corporation 2
(Date:1/22/2015)... January 23, 2015 Recently, Weddingshe.com has added ... and has announced its highest annual revenues in the past ... its popular glamorous wedding dresses. , According to the sales ... wedding dress promotions for them in 2015. This point can ...
(Date:1/22/2015)... Four years since the release of their debut recording ... marriage of Avasa & Matthew Love – the duo are pleased ... release through White Swan Records on February 24, 2015. , THE ... path available to all of us to walk out of the ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 EBSCO Information ... (AMA) are expanding their relationship in an effort to further ... the world. While EBSCO has long made AMA journals available ... sales agent for The JAMA Network. , Long ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 JJsHouse.com is a ... dresses. Today, the business announces its latest collection of ... , “The most important issue is the wedding dress on ... thing in a woman’s life. Every bride wants to find ...
(Date:1/22/2015)... Lower-Auto-Insurance.com has released a new blog post explaining the importance ... reducing the costs of an auto insurance policy . , ... lower prices for their vehicle insurance policies. The safety a vehicle ... costs. Because of this, drivers should always carry a first ...
Breaking Medicine News(10 mins):Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4Health News:Find The Most Suitable Wedding Dress At JJsHouse.com 2Health News:Driving Safe And Other Factors That Make Auto Insurance Affordable! 2
... Bristol-Myers Squibb Company,(NYSE: BMY ) will announce results ... During a conference call on October 25 at 10:30 ... will,address inquiries from investors and analysts. Investors and ... live,webcast of the call at http://www.bms.com/ir or ...
... increase the risk of bleeding from the stomach, according ... , The antidepressant drugs, selective serotonin reuptake inhibitors known ... Clinical Excellence (NICE). SSRIs are very widely used in ... last year, probably to about 1.5 million patients. , ...
... to Launch Medi-Scripts PLUS - Prescription Pads with ... ... Medi-Promotions, Inc.,the originator of Medi-Scripts(R) prescription pads, today announced that,it ... company,s next generation prescription pad model. Being launched this,month at ...
... Health Management Systems,Inc. (HMS) today announced that ... Inc. d/b/a/ Permedion, an independent health care quality ... this,acquisition, HMS augments its portfolio of program integrity ... agencies and,managed care organizations. Permedion utilizes advanced ...
... 8 /Xinhua-PRNewswire-FirstCall/ -- China Medical,Technologies, Inc. (the "Company") ... company that develops, manufactures and markets advanced in-,vitro ... systems, today announced that it has posted its ... http://ir.chinameditech.com . The 2006,annual report includes ...
... treatment for breast cancer differs between African-American women and ... insurance type. The study appears in the November 15, ... American Cancer Society. , Dr. Mousumi Banerjee of ... from Wayne State University and Dr. William Hryniuk from ...
Cached Medicine News:Health News:Antidepressants and painkillers - a dangerous combination 2Health News:Medi-Promotions Hires Industry Executive to Expand its Medi-Scripts Prescription Pad Model 2Health News:HMS Acquires Permedion to Expand Clinical Review Capabilities 2Health News:China Medical Technologies to Post 2006 Annual Report on Its Website 2Health News:Differences observed between black and white women in use of breast cancer therapy 2
... Cytometry Concentrate is for use as a ... cytometry. Each 70ml bottle of Cytometry Concentrate ... distilled water. Compared to Cubitainers, Streck Cytometry ... and saves money without compromising performance. Streck ...
... CD34 is a stabilized preparation ... can be used as a ... CD34 positive cells. It is ... ProCOUNT gating strategies. CD-Chex CD34 ...
... A lytic reagent manufactured ... determination of hemoglobin and ... Agent IIIA is manufactured ... the Abbott CELL-DYN® 1700. ...
Streck-Hemoglobin/Lyse is a lytic reagent for the quantitative determination of hemoglobin on the Abbott CELL-DYN® 3000. The shelf life is two years from the date of manufacture....
Medicine Products: